Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Novartis will acquire Tourmaline Bio for about $1.4 billion, gaining rights to pacibekitug, an experimental antibody aimed at atherosclerotic cardiovascular…
Novartis has agreed to pay $1.4 billion for Tourmaline Bio, adding a long-acting anti-IL-6 antibody to its cardiovascular pipeline in a bid to compete with…
LONDON — Novartis on Tuesday said it would buy Tourmaline Bio in a deal worth roughly $1.4 billion, picking up an experimental drug that has shown potential in…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Novartis agreed to acquire Tourmaline Bio for $48.00/share cash, total equity value ~$1.4B. Adds pacibekitug, a long-acting fully-human anti-IL-6 mAb with best-in-class potential for ASCVD. Completed late October 2025 with 92.94% shares tendered.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Tourmaline Bio, Inc. (this deal) | 2025 | $1.4B | — |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2025 deals · Novartis AG deals · Cardiovascular deals